Exploring the use and safety of a new antipsychotic for agitation in elderly patients with dementia
Determining the Utilization, Cost, and Safety of Antipsychotics Among the Elderly with Dementia Post-Brexpiprazole Approval for Agitation in Alzheimer's Disease
This study looks at how well brexpiprazole, a new medication for helping older adults with Alzheimer's and related conditions who feel restless or agitated, is being used in real life, including how much it costs and how safe it is, to see if it can make life better for both patients and their caregivers.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11039404 on NIH RePORTER |
What this research studies
This research investigates the use of brexpiprazole, the first FDA-approved medication for treating agitation in elderly patients with Alzheimer's disease and related dementias. It aims to assess how often this medication is prescribed, its associated costs, and its safety profile in real-world settings. By analyzing data on its utilization, the study seeks to understand the implications of this new treatment option for improving the quality of life for patients and reducing caregiver burden. The research will involve collecting and analyzing information from various healthcare settings to provide insights into the medication's effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are elderly individuals diagnosed with Alzheimer's disease or related dementias who experience agitation.
Not a fit: Patients who do not have Alzheimer's disease or related dementias, or those who do not exhibit agitation, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of agitation in elderly patients with dementia, enhancing their quality of life and supporting caregivers.
How similar studies have performed: Other research has shown promising results with the use of antipsychotics for managing agitation in dementia patients, but this specific approach with brexpiprazole is relatively novel.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Kim, Youngran — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Kim, Youngran
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.